Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study.

CONCLUSIONS: ΔSUVmax appears to be a powerful tool for the prediction of long-term outcome in patients with FDG-avid MM. Other prospective studies are needed to further validate this prognostic biomarker.
PMID: 30068709 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 1, 2018 Category: Cancer & Oncology Authors: Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodere F, Bodet-Milin C Tags: Clin Cancer Res Source Type: research